Orexo AB (ST:ORX): US net sales of Zubsolv (for the treatment of opioid dependence) grew 10% y-o-y to SEK124.1m in a market where volume growth was driven by the larger (46% of all subscriptions), less profitable and more competitive public segment (Zubsolv has 27% market access). Despite a testing quarter we believe the market’s view of Zubsolv’s prospects is too pessimistic; Q3/Q417 should gain from the addition of Zubsolv to the state of Wisconsin’s preferred formulary for it Medicaid programme. Additionally, Zubsolv recently gained a preferred (now reimbursable) position on the CVS Caremark 2018 formulary, taking its access to the commercial sector to over 90%. Abstral royalties, which are loaded to H217, should aid in achieving FY17 forecasts.
Zubsolv: Optimising investment to capture growth
The whole opioid dependence market grew 9.8%, but was mainly driven by the growth in the less profitable public segment where Zubsolv currently has lower market access (27%; cash: 100%; commercial: 80%), thus limiting y-o-y overall Zubsolv demand growth to 7.6%. In addition, the positive effect of stocking and currency offset the reductions in net pricing, resulting in Zubsolv y-o-y US net sales growth of 10% to SEK124.1m. Orexo is optimising its investment strategy to focus on growth in all segments including capturing market access in the public segment; the addition of Zubsolv to the state of Wisconsin’s preferred formulary should aid Q3/4 volumes.
To read the entire report Please click on the pdf File Below:
Which stock should you buy in your very next trade?
With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Unsure where to invest next? Get access to our proven portfolios and discover high-potential opportunities.
In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record.
With portfolios tailored for Dow stocks, S&P stocks, Tech stocks, and Mid Cap stocks, you can explore various wealth-building strategies.